• Changjiang Qin, Ang Li, Yafei Xiao, Wenjing Liu, Ertao Zhai, Quanying Li, Hong Jing, Yijie Zhang, Hui Zhang, Xuhui Ma, Hongna Tang, and Dan Rong.
• Department of Gastrointestinal Surgery, Huaihe Hospital of Henan University, Kaifeng, China.
• Ann. Med. 2023 Jan 1; 55 (2): 22786192278619.

BackgroundThe treatment of Colorectal cancer (CRC) is extremely complex and survival rates vary depending on the stage of the disease at the time of diagnosis. Neoadjuvant chemoradiotherapy (NACRT), is the conventional treatment for locally advanced rectal cancer (LARC); however, the resistance to chemoradiotherapy in LARC is difficult to predict.Materials And MethodsIn this study, clinical data of 126 LARC patients were collected and analyzed, and relevant validation was performed using GEO database and in vitro and in vivo experiments, including Western blotting and Real-time quantitative PCR, immunohistochemistry, immunofluorescence, clonogenic cell survival assays, and nude-mouse xenograft models.ResultsIn patients with LARC who were treated with neoadjuvant radiotherapy (NART), higher ZNF281 expression in malignant tissue was associated with a poorer prognosis and lesser degree of tumor regression. Cell and mouse experiments have shown that ZNF281 reduces the damage caused by X-rays to CRC cells and tumors grown in mice.ConclusionWe found that the expression of ZNF281 predicted the radiation response of CRC cells and suggested the prognosis of patients with LARC who received neoadjuvant radiation therapy.

19 keywords...

hide…